Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaccinations For US Teens & Adults Continue to Lag

Stockhouse Editorial
4 Comments| January 21, 2022

{{labelSign}}  Favorites
{{errorMessage}}

New data has found that vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis commissioned by global healthcare company.

GlaxoSmithKline (NYSE: GSK, Forum) brought Avalere Health on board to conduct the study.

This assessment follows two previous reports tracking the pandemic’s significant effect on routine Centers for Disease Control and Prevention-recommended vaccinations.

The report found that, cumulatively, from January 2020 to July 2021, US teens and adults may have missed an estimated 37.1 million doses of recommended vaccines compared to 2019. It is believed that the pandemic continues to negatively impact routine immunizations in the United States.

Via a media release on this report, GSK Senior Vice President and Head of US Vaccines Judy Stewart said that the pandemic has elevated the value, impact, and understanding of vaccines in helping to prevent disease and death, especially in the adult and older adult populations in the US.

"We must not lose sight of the longstanding recommendations for routine vaccines across all age groups that are often underutilized, leading to significant medical, economic and societal costs that could otherwise be prevented by timely vaccination.”

To estimate missed doses at a national level, Avalere used a market-specific, rate-based methodology to extrapolate the number of vaccine claims to the national population.

Do you agree? Let us know your thoughts in the comments below.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

As soon as health authorities prove that vaccinated people are no longer spreaders, then maybe more non vaccinated patients will buy into the vaccine. Stop the BS about the efficacy etc and let people make their own democratic choices. The non vaxed people and not the majority spreaders by any stretch of the imagination. R H
(28)
January 25, 2022

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today